TRAW - Total Utang marang Modal Traws Pharma

This chart from the GURU.Markets platform demonstrates the total debt-to-equity ratio of Traws Pharma, Inc. (TRAW), which stands at 0.00. Traws Pharma, Inc. (TRAW) develops innovative small molecules to combat resistant respiratory pathogens. Its profit is driven by government contracts and licenses for COVID-19 and influenza drugs. However, the business is exposed to risks due to its narrow specialization on a single primary candidate in development.

To assess the financial stability of Traws Pharma, Inc. (TRAW), it is essential to monitor the balance between borrowed funds and equity assets. This metric measures the proportion of total liabilities within the capital structure, and analyzing the current total liabilities-to-equity ratio helps determine whether the business is overleveraged during the R&D stage, when primary capital is generated through intellectual property and future licensing royalties.